The USA-based non-profit campaigner on patents, I-MAK, has claimed a significant victory in its bid to bring hepatitis C treatments that were previously protected by patents to the world’s largest patient population.
I-MAK, which stands for Initiative for Medicines, Access & Knowledge, brought the patent challenge relating to sofosbuvir before China’s State Intellectual Property Office (SIPO).
"A growing list of countries have found Gilead’s patents on sofosbuvir wanting and insufficient"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze